The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published recommendations that aim to facilitate the conduct of decentralised clinical trials (DCTs) while safeguarding the rights and well-being of participants as well as the robustness and reliability of the data collected.
Patrycja Buczak-Kula
Clinical Trials in the European Union (ACT EU).
https://www.ema.europa.eu/en/news/facilitating-decentralised-clinical-trials-eu
What Are Nuclear Medicine Procedures and How Are They Used in Clinical Trials? Nuclear medicine procedures (NMPs) are diagnostic and/or…
Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…
Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…
Copyright @ 2025 Axcellant